A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections

Astellas Pharma China, Inc.2,555 enrolled

Overview

The objective of this study is to evaluate the efficacy of intravenous micafungin for the empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy patients with invasive fungal infections caused by Candida sp. or Aspergillus sp. (fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.

Study Type

OBSERVATIONAL

Enrollment

2,555

Conditions

Invasive Fungal Infections

Interventions

MicafunginDRUG

Intravenous

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who received Micafungin as empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy * Patients received Micafungin treatment at least 1 dose Exclusion Criteria: * Patients received Micafungin treatment combined with other antifungal drugs at the same time * Neither efficacy or safety can be evaluated because of missing data, confused record

Locations (17)

Unnamed facility

Beijing, China

Unnamed facility

Changchun, China

Unnamed facility

Chengdu, China

Unnamed facility

Chongqing, China

Outcomes

Primary Outcomes

Overall success rate

Overall success rate=number of overall success patients/number of patients for efficacy evaluation × 100%

Time frame: Up to 12 months

Secondary Outcomes

Overall incidence and severity of adverse events

Time frame: Up to 12 months

Overall incidence and severity of adverse drug reactions

Time frame: Up to 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.